BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37216681)

  • 1. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
    Borgert CJ
    Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
    Bishop PL; Willett CE
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
    Stump DG; O'Connor JC; Lewis JM; Marty MS
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
    Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
    Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing utility of thyroid in vitro screening assays through comparisons to observed impacts in vivo.
    Eytcheson SA; Olker JH; Friedman KP; Hornung MW; Degitz SJ
    Regul Toxicol Pharmacol; 2023 Oct; 144():105491. PubMed ID: 37666444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
    Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
    Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program.
    Borgert CJ; Mihaich EM; Ortego LS; Bentley KS; Holmes CM; Levine SL; Becker RA
    Regul Toxicol Pharmacol; 2011 Nov; 61(2):185-91. PubMed ID: 21803110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
    Willett CE; Bishop PL; Sullivan KM
    Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
    LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
    Browne P; Noyes PD; Casey WM; Dix DJ
    Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction to "screening for endocrine activity-experiences with the US EPA's endocrine disruptor screening program and future considerations".
    Marty S
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):1-2. PubMed ID: 24510782
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypothesis-driven weight-of-evidence analysis of endocrine disruption potential: a case study with triclosan.
    Mihaich E; Capdevielle M; Urbach-Ross D; Slezak B
    Crit Rev Toxicol; 2017 Apr; 47(4):263-285. PubMed ID: 28128023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
    Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
    ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance weighting of tier 1 endocrine screening endpoints by rank order.
    Borgert CJ; Stuchal LD; Mihaich EM; Becker RA; Bentley KS; Brausch JM; Coady K; Geter DR; Gordon E; Guiney PD; Hess F; Holmes CM; LeBaron MJ; Levine S; Marty S; Mukhi S; Neal BH; Ortego LS; Saltmiras DA; Snajdr S; Staveley J; Tobia A
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):90-113. PubMed ID: 24510745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine profiling and prioritization of environmental chemicals using ToxCast data.
    Reif DM; Martin MT; Tan SW; Houck KA; Judson RS; Richard AM; Knudsen TB; Dix DJ; Kavlock RJ
    Environ Health Perspect; 2010 Dec; 118(12):1714-20. PubMed ID: 20826373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
    Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
    Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pronamide: Weight of evidence for potential estrogen, androgen or thyroid effects.
    Marty MS; Papineni S; Coady KK; Rasoulpour RJ; Pottenger LH; Eisenbrandt DL
    Regul Toxicol Pharmacol; 2015 Jul; 72(2):405-22. PubMed ID: 25846366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review and analysis of the potential for glyphosate to interact with the estrogen, androgen and thyroid pathways.
    Levine SL; Webb EG; Saltmiras DA
    Pest Manag Sci; 2020 Sep; 76(9):2886-2906. PubMed ID: 32608552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals.
    Rotroff DM; Dix DJ; Houck KA; Knudsen TB; Martin MT; McLaurin KW; Reif DM; Crofton KM; Singh AV; Xia M; Huang R; Judson RS
    Environ Health Perspect; 2013 Jan; 121(1):7-14. PubMed ID: 23052129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summary of the development the US Environmental Protection Agency's Medaka Extended One Generation Reproduction Test (MEOGRT) using data from 9 multigenerational medaka tests.
    Flynn K; Lothenbach D; Whiteman F; Hammermeister D; Touart LW; Swintek J; Tatarazako N; Onishi Y; Iguchi T; Johnson R
    Environ Toxicol Chem; 2017 Dec; 36(12):3387-3403. PubMed ID: 28857258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.